#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	13436	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2263	589.3	0	.	n	.	0	A69G	SNP	69	69	A	367	367	G	732	G,A	672,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	13436	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2263	589.3	0	.	n	.	0	C1450T	SNP	1450	1450	C	1748	1748	T	733	T	669	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	13436	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2263	589.3	1	SNP	n	C1184T	0	.	.	1184	1184	C	1482	1482	C	855	C	790	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24860	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3617	683.6	0	.	n	.	0	G1337A	SNP	1337	1337	G	1675	1675	A	877	A,G	807,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24860	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3617	683.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2309	2309	C	803	C,A	733,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24860	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3617	683.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2383	2383	A	808	A,G	766,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24860	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3617	683.6	1	SNP	n	C2597T	0	.	.	2597	2597	C	2935	2935	C	697	C	659	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_M_01364c	folP.WHO_M_01364c	1	1	539	1960	folP	852	852	99.77	folP.l6.c4.ctg.1	1466	132.7	0	.	p	.	0	E151K	NONSYN	451	453	GAA	749	751	AAA	187;186;186	A;A;A	170;171;169	.	.
folP.WHO_M_01364c	folP.WHO_M_01364c	1	1	539	1960	folP	852	852	99.77	folP.l6.c4.ctg.1	1466	132.7	0	.	p	.	0	V275M	NONSYN	823	825	GTG	1121	1123	ATG	182;182;179	A,G;T;G	168,1;172;170	.	.
folP.WHO_M_01364c	folP.WHO_M_01364c	1	1	539	1960	folP	852	852	99.77	folP.l6.c4.ctg.1	1466	132.7	1	SNP	p	R228S	1	.	.	682	684	AGC	980	982	AGC	201;197;197	A;G;C	192;187;186	folP.WHO_M_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4918	gyrA	2751	2751	100.0	gyrA.l6.c4.ctg.1	3479	140.7	1	SNP	p	S91F	0	.	.	271	273	TCC	638	640	TCC	172;171;172	T;C;C,T	155;153;153,1	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4918	gyrA	2751	2751	100.0	gyrA.l6.c4.ctg.1	3479	140.7	1	SNP	p	D95N	0	.	.	283	285	GAC	650	652	GAC	166;164;165	G;A;C	150;148;150	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4918	gyrA	2751	2751	100.0	gyrA.l6.c4.ctg.1	3479	140.7	1	SNP	p	D95G	0	.	.	283	285	GAC	650	652	GAC	166;164;165	G;A;C	150;148;150	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1646	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1200	135.1	0	.	p	.	0	F178L	NONSYN	532	534	TTC	839	841	CTC	156;158;157	C;T,C;C	148;149,1;146	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1646	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1200	135.1	1	SNP	p	G45D	0	.	.	133	135	GGC	440	442	GGC	207;206;208	G;G;C,A	193;193;193,1	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	862	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c17.ctg.1	922	92.8	0	.	n	.	0	A197.	DEL	197	197	A	578	578	A	184	A	175	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4748	parC	2304	2304	99.91	parC.l15.c30.ctg.1	3024	155.9	1	SNP	p	D86N	0	.	.	256	258	GAC	612	614	GAC	201;200;201	G;A;C	185;182;184	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4748	parC	2304	2304	99.91	parC.l15.c30.ctg.1	3024	155.9	1	SNP	p	S87W	0	.	.	259	261	AGT	615	617	AGT	204;204;206	A;G;T	187;190;190	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4748	parC	2304	2304	99.91	parC.l15.c30.ctg.1	3024	155.9	1	SNP	p	S87I	0	.	.	259	261	AGT	615	617	AGT	204;204;206	A;G;T	187;190;190	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4748	parC	2304	2304	99.91	parC.l15.c30.ctg.1	3024	155.9	1	SNP	p	S87R	0	.	.	259	261	AGT	615	617	AGT	204;204;206	A;G;T	187;190;190	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4748	parC	2304	2304	99.91	parC.l15.c30.ctg.1	3024	155.9	1	SNP	p	S88P	0	.	.	262	264	TCC	618	620	TCC	202;202;201	T;C;C	188;189;187	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4078	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2617	154.7	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1595	1597	GGC	213;211;209	G;G;C	195;192;191	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	3772	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2498	150.3	1	SNP	p	A311V	0	.	.	931	933	GCA	1325	1327	GCA	198;200;196	G;C;A	186;186;185	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3772	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2498	150.3	1	SNP	p	I312M	0	.	.	934	936	ATC	1328	1330	ATC	191;190;197	A;T;C	181;179;186	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3772	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2498	150.3	1	SNP	p	V316P	0	.	.	946	948	GTG	1340	1342	GTG	215;212;210	G,T;T;G	201,1;198;200	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3772	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2498	150.3	1	SNP	p	V316T	0	.	.	946	948	GTG	1340	1342	GTG	215;212;210	G,T;T;G	201,1;198;200	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3772	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2498	150.3	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1844	1846	ACC	168;169;171	A;C;C	153;158;161	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3772	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2498	150.3	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1898	1900	GCG	181;183;180	G;C,G;G	161;149,1;152	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3772	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2498	150.3	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1898	1900	GCG	181;183;180	G;C,G;G	161;149,1;152	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3772	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2498	150.3	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2021	2023	GGC	180;177;176	G;G;C	169;165;165	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3772	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2498	150.3	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2030	2032	GGC	175;173;170	G;G,T;C	163;160,1;158	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3772	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2498	150.3	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2048	2050	CTG	167;169;170	C,G;T,A;G,T	132,5;124,1;127,2	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5450	ponA	2397	2397	100.0	ponA.l15.c30.ctg.1	3254	166.9	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1666	1668	CCG	182;182;184	C;C;G	165;170;170	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2334	porA	1146	1146	99.65	porA.l15.c4.ctg.1	1746	132.7	0	.	p	.	0	M83fs	FSHIFT	247	247	A	527	527	C	150	C	138	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2654	porB1b	1047	1047	99.14	porB1b.l15.c17.ctg.1	1616	163.3	0	.	p	.	0	N38E	NONSYN	112	114	AAT	536	538	GAA	209;207;210	G;A;A	199;198;201	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2654	porB1b	1047	1047	99.14	porB1b.l15.c17.ctg.1	1616	163.3	0	.	p	.	0	N134D	NONSYN	400	402	AAT	824	826	GAT	219;220;221	G;A;T	210;208;209	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2654	porB1b	1047	1047	99.14	porB1b.l15.c17.ctg.1	1616	163.3	0	.	p	.	0	P175S	NONSYN	523	525	CCA	947	949	TCA	216;219;221	T;C;A	204;201;210	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2654	porB1b	1047	1047	99.14	porB1b.l15.c17.ctg.1	1616	163.3	0	.	p	.	0	K207E	NONSYN	619	621	AAA	1043	1045	GAA	198;199;198	G;A;A	184;184;186	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2654	porB1b	1047	1047	99.14	porB1b.l15.c17.ctg.1	1616	163.3	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1076	1078	GTC	203;200;203	G;T;C	193;191;196	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2654	porB1b	1047	1047	99.14	porB1b.l15.c17.ctg.1	1616	163.3	0	.	p	.	0	F222S	NONSYN	664	666	TTT	1088	1090	TCT	210;210;213	T;C;T	198;199;202	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2654	porB1b	1047	1047	99.14	porB1b.l15.c17.ctg.1	1616	163.3	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1406	1408	GCA	217;219;222	G;C,A;A	200;201,1;205	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2654	porB1b	1047	1047	99.14	porB1b.l15.c17.ctg.1	1616	163.3	1	SNP	p	G120K	1	.	.	358	360	AAG	782	784	AAG	234;234;232	A,G;A,G;G,T	218,1;218,1;216,1	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2654	porB1b	1047	1047	99.14	porB1b.l15.c17.ctg.1	1616	163.3	1	SNP	p	A121D	1	.	.	361	363	GAC	785	787	GAC	229;227;227	G;A,C;C	212;211,1;213	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2654	porB1b	1047	1047	99.14	porB1b.l15.c17.ctg.1	1616	163.3	1	SNP	p	D121N	0	.	.	361	363	GAC	785	787	GAC	229;227;227	G;A,C;C	212;211,1;213	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	9718	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	4854	199.4	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	1952	1954	AAT	212;215;217	A;A;T	196;199;200	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1066	rpsJ	312	312	100.0	rpsJ.l15.c30.ctg.1	1134	93.2	1	SNP	p	V57M	1	.	.	169	171	ATG	553	555	ATG	220;222;219	A;T;G	209;212;208	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
